Producing certain therapeutic proteins and biologics at high yields can be challenging, hindering the development of mRNA therapies, vaccines, and other protein-based drugs. Traditional protein expression methods often struggle with difficult-to-express proteins, leading to bottlenecks in research and manufacturing.

Avenue Biosciences offers a protein engineering platform that leverages high-throughput chemistry and machine learning to optimize protein expression. The platform analyzes thousands of N-terminal signal peptides to identify candidates that significantly improve protein yield, in some cases by up to 500%. This technology is compatible with various mammalian protein production systems, including mRNA therapies, synthetic proteins, and multi-chain proteins like monoclonal antibodies. By enhancing protein production, Avenue Biosciences aims to accelerate therapeutic development and reduce time-to-market for novel biologics.

High-throughput screening of naturally occurring and genetically engineered signal peptides

Machine learning-driven analysis to predict and optimize protein expression

Demonstrated yield improvements of up to 500% in external validations

Compatible with diverse protein production systems, including mammalian cell lines

Enables production of difficult-to-express proteins that hinder therapeutic development

Facilitates single-chain and multi-chain protein expression optimization

The primary target audience includes biopharmaceutical companies, biotechnology firms, and research institutions involved in developing protein biologics, mRNA therapies, vaccines, and other protein-based therapeutics.